Xelpac 6 mg/ml Vial30 mg

Xelpac 6 mg/ml Vial 30 mg is an intravenous chemotherapy medicine used, as part of an oncologist-directed treatment plan, for:

• Ovarian cancer: first-line and subsequent treatment of advanced ovarian cancer, in combination with other chemotherapy agents (typically a platinum agent)
• Breast cancer: adjuvant treatment of node-positive breast cancer, given sequentially with standard chemotherapy; and treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy
• Non-small cell lung cancer (NSCLC): first-line treatment, in combination with cisplatin, in patients who are not candidates for potentially curative surgery or radiation therapy
• AIDS-related Kaposi's sarcoma: second-line treatment

Contains Xelpac 6 mg/ml Vial 30 mg as the active ingredient, supplied as a concentrate for solution for infusion, requiring dilution before intravenous administration. Vial strengths and concentrations vary by manufacturer.

Xelpac 6 mg/ml Vial 30 mg is an intravenous chemotherapy medicine derived from the yew tree, used to treat several cancers, including ovarian, breast, and non-small cell lung cancer. It works by stabilizing the internal skeleton (microtubules) of cancer cells in a way that prevents them from dividing normally, ultimately causing cell death. Xelpac 6 mg/ml Vial 30 mg is formulated with a solvent (Cremophor EL) that is itself associated with a significant risk of severe hypersensitivity reactions, which is why every patient must receive specific premedication before each infusion, regardless of whether a previous infusion was well tolerated.

Therapeutic Class: Antineoplastic (Chemotherapy) Agent

Xelpac 6 mg/ml Vial 30 mg is extensively protein-bound and metabolized in the liver, primarily by CYP2C8 and CYP3A4 enzymes, with excretion mainly through the bile and faeces. The formulation uses a solvent (polyoxyethylated castor oil, Cremophor EL) to dissolve the poorly water-soluble drug, and this solvent itself is a recognized contributor to the hypersensitivity reactions seen with Xelpac 6 mg/ml Vial 30 mg, which is why mandatory premedication is required before every dose rather than only after a reaction occurs.

• Given only by intravenous infusion, by trained oncology healthcare professionals, using non-PVC tubing and in-line filtration as required by the specific formulation
• All patients must be premedicated before every infusion - typically with a corticosteroid (such as dexamethasone), an antihistamine (such as diphenhydramine), and an H2-receptor antagonist (such as cimetidine or ranitidine), to reduce the risk of severe hypersensitivity reactions
• Complete blood counts are checked before each cycle, and treatment is delayed or the dose modified if blood counts are too low
• Patients are monitored closely, particularly during the first and second infusions, for signs of a hypersensitivity reaction

The following should be assessed and managed by the treating oncology team:

• Strong CYP2C8 or CYP3A4 inhibitors or inducers (such as ketoconazole, rifampicin, or certain anticonvulsants): may significantly alter Xelpac 6 mg/ml Vial 30 mg blood levels and toxicity.
• Cisplatin, when given before Xelpac 6 mg/ml Vial 30 mg: can reduce Xelpac 6 mg/ml Vial 30 mg clearance and increase toxicity; Xelpac 6 mg/ml Vial 30 mg is generally given before cisplatin in combination regimens for this reason.
• Doxorubicin: Xelpac 6 mg/ml Vial 30 mg may increase doxorubicin blood levels if given before it; specific sequencing is used in combination regimens to manage this interaction.
• Other myelosuppressive chemotherapy or radiation therapy: combined use increases the risk and severity of low blood counts; dosing is carefully coordinated within combination regimens.
• Live vaccines: should generally be avoided during and for a period after Xelpac 6 mg/ml Vial 30 mg treatment, given significant immune suppression.

Common side effects

• Hair loss (alopecia) - nearly universal, typically reversible after treatment
• Nausea, vomiting, diarrhoea
• Fatigue
• Muscle and joint pain (arthralgia/myalgia), particularly 2-3 days after infusion
• Mild to moderate peripheral neuropathy (numbness, tingling)

Serious side effects (require prompt medical attention)

• Severe hypersensitivity reactions, including anaphylaxis: dyspnea and low blood pressure requiring treatment, angioedema, generalized urticaria - occur in 2-4% of patients despite premedication, generally within the first hour of infusion; fatal reactions have occurred despite premedication. Patients who experience a severe reaction should not be rechallenged with Xelpac 6 mg/ml Vial 30 mg.
• Myelosuppression: significantly reduced blood counts, particularly neutrophils, with associated infection risk; the most common dose-limiting toxicity.
• Severe peripheral neuropathy: can be dose-limiting; report worsening numbness, tingling, or weakness in the hands or feet promptly.
• Cardiac conduction abnormalities: continuous cardiac monitoring is not routinely required except in patients with serious pre-existing conduction abnormalities; monitoring is recommended when combined with doxorubicin.
• Signs of infection during periods of low blood counts: fever, chills.

Pregnancy

Xelpac 6 mg/ml Vial 30 mg can cause fetal harm and should not be used during pregnancy. Effective contraception is recommended for patients of reproductive potential during treatment and for a period afterward, as advised by the treating oncologist.

Breastfeeding

Xelpac 6 mg/ml Vial 30 mg is contraindicated during breastfeeding; it is not known whether it passes into human milk, but given the potential for serious adverse effects in a nursing infant, breastfeeding should be discontinued during treatment.

• Mandatory premedication: all patients must be premedicated with a corticosteroid, antihistamine, and H2-antagonist before every infusion to reduce (though not eliminate) hypersensitivity reaction risk.
• Hypersensitivity monitoring: patients should be observed closely, particularly during the first hour of each infusion; facilities for managing severe reactions must be available.
• Myelosuppression: monitor blood counts frequently; do not repeat courses until neutrophil and platelet counts have recovered to safe thresholds.
• Peripheral neuropathy: monitor for worsening symptoms; dose reduction is required for severe neuropathy.
• This medicine should only be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents, in facilities equipped to manage complications.

Overdose would be expected to cause exaggerated known toxicities, particularly severe myelosuppression, mucositis, and peripheral neuropathy. There is no specific antidote; management is supportive, provided in a specialist facility, including blood count monitoring, transfusion support, and treatment of any resulting infection, under the direct management of the oncology treatment team.

Store unopened vials at controlled room temperature, protected from light, as directed by the specific manufacturer. Diluted infusion solutions should be used within the manufacturer's specified time frame; dispose of unused cytotoxic medicine according to institutional protocols for hazardous pharmaceutical waste.

• Elderly: May have an increased incidence of certain adverse events, including cardiovascular events and peripheral neuropathy; used with the same weight-based dosing approach, with careful monitoring.
• Hepatic impairment: Dose adjustment is generally required, given hepatic metabolism; guided by the treating oncologist based on liver function tests.
• Renal impairment: Limited specific dose adjustment guidance is available; use with caution.

Treatment continues in cycles, typically every 3 weeks (or every 2 weeks for some Kaposi's sarcoma regimens), for a defined number of cycles in the adjuvant breast cancer setting, or for as long as the cancer responds and the patient tolerates therapy in other settings, as determined by the treating oncologist based on periodic reassessment of disease response and toxicity.

Xelpac 6 mg/ml Vial 30 mg concentrate must be diluted in an appropriate IV fluid (commonly normal saline, D5W, or a similar solution) to a specified final concentration before infusion, following the specific product's instructions, and administered through non-PVC tubing with an in-line filter (0.22 micron or finer) due to the risk of leaching from the Cremophor EL solvent. The diluted solution should be used within the manufacturer's specified stability window.

Drug Class: Taxane (microtubule-stabilizing agent)

Xelpac 6 mg/ml Vial 30 mg binds to tubulin, a protein that forms microtubules, the internal "skeleton" cells use for structural support and to separate their chromosomes during division. Unlike drugs that prevent microtubules from forming, Xelpac 6 mg/ml Vial 30 mg promotes their assembly and then abnormally stabilizes them, preventing the normal disassembly needed for a cell to complete division. This disrupts the cell division process, particularly affecting rapidly dividing cancer cells, and ultimately triggers cell death.

Xelpac 6 mg/ml Vial 30 mg is primarily used in adult oncology practice for the cancers listed under indications; established pediatric dosing and safety data are limited, and any pediatric use would generally occur under specialist pediatric oncology supervision as part of a specific treatment protocol.